caplacizumab
sanofi
['caplac', 'sanofi']
george goshua argued against the use of caplacizumab in immune ttp in the #ash22 debate. he based his argument on issues dealing with safety, efficacy and cost effectiveness. #ttp 
Professor of Haemostasis and Thrombosis in Sheffield, UK. I tweet about thrombosis, hemophilia, COVID-19, medicine & NHS. Opinions are my own.